Another in our occasional series demystifying Latin American banking trojans

The post Grandoreiro: How engorged can an EXE get? appeared first on WeLiveSecurity

…and why are they selling it to other security vendors and product testers?

The post Professional data leakage: How did that security vendor get my personal data? appeared first on WeLiveSecurity

An unknown threat actor is exploiting vulnerabilities in plugins for which patches have been available for months, or even years

The post Almost a million WordPress websites targeted in massive campaign appeared first on WeLiveSecurity

Source: Streetwise Reports   05/01/2020

Seattle Genetics Inc. (SGEN:NASDAQ) yesterday announced financial results for the first quarter ended March 31, 2020.

The company also provided an update on commercial results achieved in the quarter for its lead medicines including ADCETRIS® (brentuximab vedotin) and PADCEV^™ (enfortumab vedotin-ejfv) and the U.S. Food and Drug Administration's (FDA) approval and launch of TUKYSA^™ (tucatinib).

The company's President and CEO Clay Siegall, Ph.D., commented, "We have had a remarkable start to 2020, delivering record product sales in the first quarter that are now coming from both ADCETRIS and PADCEV. Notably, strong PADCEV sales in the first full quarter of launch reflect the unmet need among patients with metastatic bladder cancer...With the recent approval of TUKYSA for patients with metastatic HER2-positive breast cancer, we have now launched our third product just four months after our second...We are also preparing for European commercial operations and have hired general managers in major European markets ahead of potential ex-U.S. approvals of TUKYSA. With two new products, growing revenues, and an advancing pipeline of novel cancer programs, we have exciting prospects for future growth."

The company highlighted that ADCETRIS net sales in the U.S. and Canada increased by 22% to $164.1 million in Q1/20, compared to $135 million in Q1/19. The firm indicated that PADCEV net sales in the U.S. reached $34.5 million in Q1/20, which was its first full quarter of commercialization. The company added that royalty revenues in Q1/20 were $20.4 million and collaboration and license agreement revenues in Q1/20 totaled $15.6 million.

The firm reported a net loss for Q1/20 of $168.4 million, or $0.98 per diluted share, compared to net loss of $13.3 million, or $0.08 per diluted share for Q1/19. The company explained that "the net loss in Q1/20 included a net investment loss of $59.1 million primarily associated with its common stock holdings in Immunomedics, which are marked-to-market, compared to a net investment gain of $38.1 million in Q1/19."

The company advised that its TUKYSA was approved by the FDA for patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2 regimens in the metastatic setting. The firm mentioned that it also expects to be able to report topline data in late Q2/20 or Q3/20 for the innovaTV 204 pivotal trial of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment.

The company noted that it is regularly monitoring the effects of the COVID-19 situation and is maintaining its business outlook estimates for FY/20 that it provided previously on February 6, 2020. For FY/20 it expects ADCETRIS net product sales of $675–700 million, royalty revenues of $105–115 million and collaboration and license agreement revenues of $30–50 million. The firm advised that for FY/20 it expects that R&D expenses will range from $860–950 million with SG&A expenses of $475–525 million.

Seattle Genetics is headquartered in Bothell, Wash., and is a global biotechnology company focused on discovering and commercializing cancer medicines.

Seattle Genetics has a market capitalization of around $23.7 billion with approximately 172.5 million shares outstanding. SGEN shares opened 2.75% higher today at $141.00 (+$3.77, +2.75%) over yesterday's $137.23 closing price and reached a new 52-week high price this morning of $157.00. The stock has traded today between $140.05 and $157.00 per share and is currently trading at $148.51 (+$11.28, +8.22%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: SGEN:NASDAQ, )

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

My new book LOSERTHINK, available now on Amazon https://tinyurl.com/rqmjc2a Content: Hydroxychloroquine as a game-changer Winning a Pulitzer A logical back to work metric Yearly flu death numbers aren’t real Remdesivir does NOT change survival rate The FBI’s reputation If you would like my channel to have a wider audience and higher production quality, please donate […]

The post Episode 955 Scott Adams: Extra Cussing Tonight. Put the Kids to Bed. Close Your Windows, Get Under the Covers appeared first on Scott Adams' Blog.

My new book LOSERTHINK, available now on Amazon https://tinyurl.com/rqmjc2a Content: Watching Anderson Cooper CNN is like being on mushrooms Why state governments are best for reopening decisions Disbanding the task force, it’s time Moonface Ben Shapiro’s clear description of coronavirus situation If you would like my channel to have a wider audience and higher production […]

The post Episode 957 Scott Adams: Let Me Tell You About the Psychedelic Mushroom I Accidentally Ingested Called CNN appeared first on Scott Adams' Blog.

My new book LOSERTHINK, available now on Amazon https://tinyurl.com/rqmjc2a Content: The coronavirus pandemic viewed through a Dilbert filter Victor David Hanson: “credentialed class” keeps getting it wrong My Twitter debate with a doctor, on testing feasibility Models function is to manipulate perception Paying to have airline middle seats empty If you would like my channel […]

The post Episode 958 Scott Adams: Grab Your Beverage and Buckle Up appeared first on Scott Adams' Blog.

My new book LOSERTHINK, available now on Amazon https://tinyurl.com/rqmjc2a Content: Adam Schiff lied for years…but broke no laws We do NOT know if Russia hacked DNC? Law enforcement targeted/framed President Trump to take him out “Cheryl The Server” theory applied to the lockdown If you would like to enjoy this same content plus bonus content […]

The post Episode 964 Scott Adams: Grab Your Beverage Because it’s Time For… appeared first on Scott Adams' Blog.

IDEX Biometrics...

This project, along with two other new projects, increases the company's order backlog by 65%.

Shares of Energous Corp. skyrocketed after the company reported that it received certification from the FCC for its new, "groundbreaking" over-the-air, power-at-a-distance wireless charging WattUp® technology.

Shares of ION Geophysical traded higher after the company reported Q1/20 financial results that included a 53% year-over-year increase in revenue.

A new study has conducted a preliminary investigation into the design of reserves that would help protect coral reefs from climate change. The results indicate that, 15 per cent of coral reefs in the Bahamas, the study area, would be able to withstand rising temperature, and would therefore be appropriately placed in reserves.

Cities are key players in global greenhouse gas (GHG) emissions. A new World Bank study has proposed a three-stage plan for mitigating climate change at a local level. Its recommendations include improving urban infrastructure and encouraging lifestyle change, but most importantly, clarity in the way urban GHG inventories are calculated.

Bycatch (species caught unintentionally in fisheries) in some commercial marine fisheries is the main cause of death in some populations of seabirds, sea turtles, marine mammals, sharks and fish. New research has revealed that bycatch from tuna fishing can be reduced by using better equipment, without compromising industry profits. However, significant policy efforts are needed to monitor bycatch and enforce more sustainable fishing practices.

Urban planning policy has had a powerful influence on the amount of green space in cities, according to a recent UK study. It found that a change in planning policy in 2000 led to a decline in urban green space in nine cities between 2001 and 2006, although the amount of green space in all but one of the cities studied has increased overall since 1991.

A new study indicates that water management in the Netherlands uses a reliable warning system for extreme weather, which can incorporate wind and coastal surge level forecasts, as well as precipitation forecasts.

Urban vegetation could have been overlooked as valuable above-ground carbon storage, according to researchers. They estimated that 231,521 tonnes of carbon were stored in above-ground vegetation in a UK city, the majority of which (97 per cent) in trees. This was 10 times the amount estimated from national figures for the same city area.

For the first time, researchers have applied a carbon footprint analysis to calculate carbon sequestration by an urban green space. Their results indicate that urban green space can act as a carbon sink, but its design and maintenance influence the amount stored.

Stricter management of fisheries is needed to prevent overexploitation and decline of tuna and their mackerel relatives, according to an international study. The researchers say fisheries managers have wrongly treated upper limits for catches as target levels for fishing, contributing to global declines and the threatened status of some species.

City dwellers who grow their own fruit and vegetables may be consuming high levels of pollutants. In a recent study, researchers found that vegetables grown on plots in Berlin, Germany, often contained higher concentrations of some heavy metals than shop-bought vegetables, with those grown close to busy roads containing the greatest quantities.

A new tool has been developed, with input from the public, to measure and compare the quality of green spaces in urban areas. A UK case study suggests that litter and vandalism are among the factors most likely to prevent local residents from using and benefiting from green spaces.

The last two decades have seen a series of new construction waste policies management in Hong Kong. One of the most significant is an offsite construction waste sorting (CWS) programme which, since its implementation in 2006, has separated 5.11 million tonnes of construction waste into different materials. The researchers suggest that the study provides an important reference for other countries working to minimise construction waste.

The impact of polluted urban soil on trees is highlighted in a recent study from Latvia. The researchers found that high salt levels from de-icing chemicals and nutrient imbalance in soil damaged lime trees growing in the city of Riga.

A new tool to improve the measurement of waste management performance has been presented by a recent study. The researchers applied it to three high consuming cities aspiring to ???zero waste???, finding San Francisco to be closer to achieving zero waste than Stockholm and Adelaide, due to its emphasis on reusing solid waste.

A recent study has revealed how water use has changed across the world over the last 60 years. Growing populations and economic development, particularly in newly-emerging countries, have increased water demand, but technological developments have led to water efficiencies and savings, which moderate these demands.

Research into mercury has identified two genes in bacteria that appear to be required for turning the metal into its most toxic form, methylmercury. The study adds to a growing body of research that helps us to understand the transformations that mercury undergoes in the environment and the microbes involved in these transformations.

Neither the public nor conservation managers are fully aware of the different risks posed by invasive alien species (IAS), new research suggests. A study examining perceptions of five invasive species in the UK shows that both conservation managers and the public regard some highly damaging species as ???low risk???, and that their awareness does not increase with the amount of scientific research on the topic.

The world’s marine ecosystems are at risk of sudden and damaging changes. The authors of a recent study say that co-ordinated management of the many drivers of marine changes, such as overfishing and pollution, is needed across international, national and local scales to help avoid the ‘regime shifts’ that affect ecosystem services and human wellbeing.

Damage caused by boats anchoring in seagrass meadows off the coast of Sardinia continues despite restrictions, new research shows. The study's authors provide a number of recommendations to help protect seagrass. These include creating special anchoring areas in seagrass-free locations, and limiting the number of boats that enter a marine protected area.

Increases in the amount of CO₂ in the atmosphere can be beneficial to crops, by providing a source of carbon for growth. However, very high levels of CO₂ have the reverse effect, decreasing the yield and quality of vegetable crops, a new study has shown. The researchers say atmospheric CO₂ concentration should be kept below 5 000 ppm to enhance the yield of leafy vegetables such as cabbage and lettuce.

Improved public communications and standardised collection systems can greatly increase uptake of safe and sustainable waste electrical and electronic equipment (WEEE) disposal and recycling. This is according to new insights from Italy and Romania, where WEEE collection rates have risen in response to these measures.

A new tool to improve the measurement of waste management performance has been presented by a recent study. The researchers applied it to three high consuming cities aspiring to ‘zero waste’, finding San Francisco to be closer to achieving zero waste than Stockholm and Adelaide, due to its emphasis on reusing solid waste.

New research has compared the environmental impact of four alternative methods of water supply in Copenhagen. Results indicated that rain and stormwater harvesting is the most environmentally sound approach, whilst desalination currently has a large environmental impact, mainly due to electricity use. However, if freshwater extraction is included as an impact, the environmental credibility of desalination is improved.

Increasing resource efficiency is a central aim of European environmental policy, and effective waste management must play a key role in this. A new report assesses waste management in 32 European countries, and identifies key lessons. Landfill taxes and mandatory separate collections of different waste types are highlighted as particularly successful policy instruments.

Individuals can assess how their behaviour is affecting nitrogen pollution with a newly developed nitrogen footprint calculator, which was developed by a team from the University of Virginia (U.S.) and the Energy Research Centre (ECN, the Netherlands). For many people in wealthy countries, reducing protein consumption to the recommended levels and reducing the amount of red meat and energy they consume would significantly lower their nitrogen footprint.

Using high-strength concrete in construction could help to reduce its impact on the environment, according to a study by French researchers. The researchers compared the environmental impacts of bridges built from ordinary and high-strength concrete and found that the high-strength solution had a lower impact on the environment overall.

A new study indicates that ‘commitment’ interventions are effective in encouraging environmentally-friendly behaviour, both in the short- and long-term. However, to increase the effectiveness of such interventions, whereby people promise or pledge to perform certain behaviours, more research is needed on the psychological processes behind their effects.

Microsoft Edge is now giving users the ability to hide those pesky browser notification dialog boxes that are commonly used by web sites to push their content, or even spam, on visitors. [...]